Provider review, September 2026
REMEVi charges one flat figure for a four-week subscription and applies it to both compounds it sells and to all three delivery routes of one of them. It also says four weeks rather than month, which is the correct unit and one that costs a buyer an extra charge a year that no page here converts for them.
REMEVi is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Both product pages state the price as a four-week subscription, in the pricing block and again in a summary line above it. Neither page calls it a month.
That distinction is worth a full extra charge every year. Thirteen four-week periods fit into a calendar year and twelve months do not, so a comparison that reads this as a monthly rate understates what a buyer actually spends.
This site records it as a figure that is not a monthly rate, with the unit written into the qualifier. On a board that sorts by monthly cost, that marking is the difference between an honest row and a flattering one.
What the seller does not do is finish the arithmetic. Nothing on either page converts four-week billing into an annual number, so a reader has to notice the unit and then do the multiplication themselves.
The same figure covers both compounds. On the cellular-coenzyme page it covers three delivery routes as well — injection, nasal spray and oral dropper — and the page says so under a heading making the point explicitly.
That is unusual and useful. On most sellers here the route changes the price, so a reader choosing a nasal spray over a needle is also choosing a different bill. Here the choice is clinical rather than financial.
The figure is stated to be all-inclusive: the clinical evaluation, the prescription filled by a licensed compounding pharmacy, injection supplies, instructions and shipping.
It is also labelled founder's pricing. That is a seller saying the rate is introductory without saying when it stops being the rate, and a reader should treat it as a figure with an unstated expiry rather than a settled price.
Both pages carry the same statement in their own words: what is prescribed here is a non-approved compounded medication, prepared by a state-licensed United States compounding pharmacy under an individual prescription, that is not a generic version of any approved drug and has not been clinically studied as a finished product.
That is a complete and unusually careful description of the category, and it sits in the body of the page rather than in a footer.
The pages add that a provider may decline to prescribe if the clinical picture does not support it, which is a sentence most sellers in this market avoid writing.
A named reviewer with a licence number is credited on both pages with a review date. No certificate of analysis or purity report appears anywhere in the text read; the quality claim rests on a merchant-certification badge, which is a different kind of assurance.
Both pages print a coverage count in their own words: fifty-one jurisdictions, described as fifty states plus the District of Columbia. A seller printing the count and the composition rather than a vague nationwide claim is easier to check.
This roster's state field carries states only, so the District of Columbia half of that claim is recorded on the row in prose rather than dropped.
A limited liability company is named in the footer of both pages, alongside an office label.
The intake, the care and the follow-up are advertised in English and Spanish, and the site carries its own Spanish route. That is stated as a service rather than left to a browser translation.
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Read the full Trellis Vitality review
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis VitalityNo, and the seller says so. It is a four-week subscription. Thirteen four-week periods fall in a year, so it costs one charge more annually than a monthly rate of the same size.
Not for the cellular coenzyme. The same figure covers the injection, the nasal spray and the oral dropper, and the page says so under a heading of its own.
The seller's own label for the rate. It signals an introductory price without saying when it ends, so it should be read as a figure with an unstated expiry.
Its pages claim fifty-one jurisdictions, described as fifty states plus the District of Columbia.
No, and both pages say so plainly: non-approved compounded preparations, not generics of any approved drug, not studied as finished products.
REMEVi is not a paid partner; this link may earn a commission if that changes. Full disclosure.